Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia
– In preclinical models, TYRA-300 demonstrated significant increases in growth and bone length--Phase 2 clinical study for pediatric…
Tyra Biosciences
Established in 2018, The Chandler Project provides advocacy, awareness, research and support to those affected by achondroplasia, the most common form of dwarfism, and other skeletal dysplasias. TCP hosts the only event in North Amercia that brings together members of the skeletal dysplasia community physicians, researchers, biotech industries and more together at the annual Achondroplasia + Skeletal Dysplasia Research Conference.